Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Sep 16;9(9):e107767.
doi: 10.1371/journal.pone.0107767. eCollection 2014.

Finding candidate drugs for hepatitis C based on chemical-chemical and chemical-protein interactions

Affiliations

Finding candidate drugs for hepatitis C based on chemical-chemical and chemical-protein interactions

Lei Chen et al. PLoS One. .

Abstract

Hepatitis C virus (HCV) is an infectious virus that can cause serious illnesses. Only a few drugs have been reported to effectively treat hepatitis C. To have greater diversity in drug choice and better treatment options, it is necessary to develop more drugs to treat the infection. However, it is time-consuming and expensive to discover candidate drugs using experimental methods, and computational methods may complement experimental approaches as a preliminary filtering process. This type of approach was proposed by using known chemical-chemical interactions to extract interactive compounds with three known drug compounds of HCV, and the probabilities of these drug compounds being able to treat hepatitis C were calculated using chemical-protein interactions between the interactive compounds and HCV target genes. Moreover, the randomization test and expectation-maximization (EM) algorithm were both employed to exclude false discoveries. Analysis of the selected compounds, including acyclovir and ganciclovir, indicated that some of these compounds had potential to treat the HCV. Hopefully, this proposed method could provide new insights into the discovery of candidate drugs for the treatment of HCV and other diseases.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Similar articles

Cited by

References

    1. Chander G, Sulkowski MS, Jenckes MW, Torbenson MS, Herlong HF, et al. (2002) Treatment of chronic hepatitis C: a systematic review. Hepatology 36: S135–144. - PubMed
    1. Approval of Incivek (telaprevir), a direct acting antiviral drug (DAA) to treat hepatitis C (HCV). Available: http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/ucm256328.... Accessed 2014 March 7.
    1. Approval of Victrelis (boceprevir) a direct acting antiviral drug (DAA) to treat hepatitis C virus (HCV). Available: http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/ucm255413.... Accessed 2014 March 7.
    1. Zhu Y, Chen S (2013) Antiviral treatment of hepatitis C virus infection and factors affecting efficacy. World J Gastroenterol 19: 8963–8973. - PMC - PubMed
    1. Zheng M, Liu Z, Xue C, Zhu W, Chen K, et al. (2006) Mutagenic probability estimation of chemical compounds by a novel molecular electrophilicity vector and support vector machine. Bioinformatics 22: 2099–2106. - PubMed

Publication types

Substances

LinkOut - more resources